SLC5A2 and type 2 diabetes mellitus: Randomized controlled trials (RCTs) demonstrate sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) reduce hospitalizations for heart failure (HF) and mortality in general older populations with type 2 diabetes (Zinman et al., 2015; Perkovic et al., 2018; Filion et al., 2020).